[go: up one dir, main page]

WO2003039487A3 - Cyclo(prolyl-glycine) et procedes utilises pour traiter des troubles neuronaux - Google Patents

Cyclo(prolyl-glycine) et procedes utilises pour traiter des troubles neuronaux Download PDF

Info

Publication number
WO2003039487A3
WO2003039487A3 PCT/US2002/036235 US0236235W WO03039487A3 WO 2003039487 A3 WO2003039487 A3 WO 2003039487A3 US 0236235 W US0236235 W US 0236235W WO 03039487 A3 WO03039487 A3 WO 03039487A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclo
methods
prolyl
glycine
neural disorders
Prior art date
Application number
PCT/US2002/036235
Other languages
English (en)
Other versions
WO2003039487A2 (fr
Inventor
Jian Guan
Peter David Gluckman
Frank Sieg
Original Assignee
Neuronz Ltd
Neuronz Biosciences Inc
Jian Guan
Peter David Gluckman
Frank Sieg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd, Neuronz Biosciences Inc, Jian Guan, Peter David Gluckman, Frank Sieg filed Critical Neuronz Ltd
Priority to AU2002340465A priority Critical patent/AU2002340465A1/en
Publication of WO2003039487A2 publication Critical patent/WO2003039487A2/fr
Publication of WO2003039487A3 publication Critical patent/WO2003039487A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des modes de réalisation de compositions pharmaceutiques comprenant cyclo(Pro-Gly) et des procédés de leur utilisation dans le traitement de la dégénérescence neuronale. Les cyclo-PG empêchent sensiblement la dégénérescence neuronale toxique et la mort cellulaire et favorisent la croissance des neurites dans les neurones, notamment dans les neurones cérébelleux. Les effets neuroprotecteurs et neurorégénératifs des cPG sont utiles pour traiter les carences neurologiques comportementales liées aux voies de régulation de l'activité motrice.
PCT/US2002/036235 2001-11-09 2002-11-12 Cyclo(prolyl-glycine) et procedes utilises pour traiter des troubles neuronaux WO2003039487A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002340465A AU2002340465A1 (en) 2001-11-09 2002-11-12 Cyclo(prolyl-glycine) and methods of use to treat neural disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NZ51537101 2001-11-09
NZ515371 2001-11-09
NZ515432 2001-11-13
NZ51543201 2001-11-13
NZ51555101 2001-11-16
NZ515551 2001-11-16

Publications (2)

Publication Number Publication Date
WO2003039487A2 WO2003039487A2 (fr) 2003-05-15
WO2003039487A3 true WO2003039487A3 (fr) 2004-01-15

Family

ID=27353943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036235 WO2003039487A2 (fr) 2001-11-09 2002-11-12 Cyclo(prolyl-glycine) et procedes utilises pour traiter des troubles neuronaux

Country Status (2)

Country Link
AU (1) AU2002340465A1 (fr)
WO (1) WO2003039487A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067425B2 (en) * 2003-09-03 2011-11-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use
US8519127B2 (en) * 2003-09-03 2013-08-27 Mike John Bickerdike Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
WO2010104093A1 (fr) * 2009-03-10 2010-09-16 参天製薬株式会社 Agent prophylactique ou thérapeutique destiné à des troubles du nerf optique comprenant un dérivé ou un sel de l'acide 4,6-dichloro-1h-indole-2-carboxylique comme principe actif
CN105902999A (zh) * 2016-02-01 2016-08-31 四川好医生攀西药业有限责任公司 一种治疗消化性溃疡的药物组合物及其制备方法和应用
CN105879005A (zh) * 2016-02-01 2016-08-24 四川好医生攀西药业有限责任公司 一种治疗溃疡性结肠炎的药物组合物及其制备方法和应用
CN105879006A (zh) * 2016-02-01 2016-08-24 四川好医生攀西药业有限责任公司 一种治疗糖尿病足溃疡的药物组合物及其制备方法和应用
CA3074193A1 (fr) * 2017-08-28 2019-03-07 Vitality Wellness (Nz) Limited Ameliorations de l'analyse d'igf-1, de l'ajustement et de la gestion de maladie d'etats non neurologiques et/ou neurologiques
JP6598412B1 (ja) * 2019-06-04 2019-10-30 ゼライス株式会社 認知機能改善用食品
AU2021259185A1 (en) 2020-04-20 2023-01-05 Lloyd Hung Loi TRAN Methods for the prophylaxis and treatment of covid and COVID-19
EP4452270A1 (fr) * 2021-12-17 2024-10-30 The Cgp Lab Limited Sources animales, fongiques et marines de cgp et concentration de cgp accrue pour la gestion de maladies et pour le traitement d'états non neurologiques et/ou neurologiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013650A2 (fr) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] OSTROVSKAYA ET AL.: "GVS-111, novel dipeptide cognition enhancer", XP002970721, accession no. STN Database accession no. 1998:597878 *
GUDASHEVA ET AL.: "Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain", FEBS LETTERS, vol. 391, 1996, pages 149 - 152, XP002970720 *
PROCEEDINGS OF THE EUROPEAN PEPTIDE SYMPOSIUM, 24TH, 1996, EDINBURGH *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US11090303B2 (en) 2018-05-15 2021-08-17 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
US12070458B2 (en) 2018-05-15 2024-08-27 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders

Also Published As

Publication number Publication date
AU2002340465A1 (en) 2003-05-19
WO2003039487A2 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003039487A3 (fr) Cyclo(prolyl-glycine) et procedes utilises pour traiter des troubles neuronaux
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
WO2004096216A3 (fr) Utilisation de riluzole dans le traitement de maladies caracterisees par l'hyperproliferation de keratinocytes, en particulier la dermatite atopique et le psoriasis
WO2001090129A3 (fr) Traitement prophylactique et therapeutique de maladies infectieuses et autres avec des composes a base de mono- et disaccharides
WO2007022470A3 (fr) Methodes et compositions pour le traitement de maladies neurologiques
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
HUS1300069I1 (hu) Dextrometorfánt és kinidint tartalmazó gyógyászati készítmények neurológiai rendellenességek kezelésére
WO2004031350A3 (fr) Modulation de l'expression du gene forkhead box o1a
WO2005039504A3 (fr) Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
WO2006105359A3 (fr) Methodes pour stimuler la pousse des cheveux par administration de proteines bmp
WO2005030240A3 (fr) Produits vegf-c ou vegf-d et methodes de stimulation des cellules souches neurales
WO2006074114A3 (fr) Compositions comportant des derives de o-acetylsalicyle de glucides amines et d'acides amines
WO2006110298A3 (fr) Nouveaux composes
WO2008157791A3 (fr) Procédés et compositions pour stimuler la neurogenèse et inhiber une dégénérescence neuronale à l'aide d'isothiazolopyrimidinones
AU2002247876A1 (en) Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
WO2007035722A8 (fr) Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale
WO2005023815A3 (fr) Composes neuroprotecteurs bicycliques et procedes d'utilisation correspondants
WO1999063978A3 (fr) Methodes de traitement de l'infection microbienne et formulations therapeutiques prevues a cet effet
WO2005014814A3 (fr) Aptameres a coiffes 5'- et 3'- et utilisations associees
WO2002030357A3 (fr) Composes et procedes servant a moduler la fonction de ccr4
WO2003039453A3 (fr) Compositions de peroxyde de dibenzoyle pour le traitement de troubles dermatologiques, et procedes d'utilisation correspondants
WO2006009975A3 (fr) Utilisation d'histamine et de composes associes pour traiter des troubles de la fonction musculaire
AU2002241343A1 (en) Decoy compositions for treating and preventing brain diseases and disorders
WO2004037165A3 (fr) Monoxyde d'azote et sa valeur biomedicale
WO2003102185A3 (fr) Procedes et compositions pour traiter une neoplasie associee aux molecules d'acides nucleiques de a1 et a2 de hnrnp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP